Royalty Historical Balance Sheet

RPRX Stock

USD 26.43 0.03 0.11%

Trend analysis of Royalty Pharma Plc balance sheet accounts such as Other Liabilities of 2.4 M, Accounts Payable of 15.9 M, Cash of 343.9 M or Other Assets of 16.3 B provides information on Royalty Pharma's total assets, liabilities, and equity, which is the actual value of Royalty Pharma Plc to its prevalent stockholders. By breaking down trends over time using Royalty Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Royalty Pharma Plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Royalty Pharma Plc is a good buy for the upcoming year.

Royalty Pharma Inventory

1.09

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Royalty Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Royalty Pharma Plc at a specified time, usually calculated after every quarter, six months, or one year. Royalty Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Royalty Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Royalty currently owns. An asset can also be divided into two categories, current and non-current.

Royalty Pharma Balance Sheet Chart

At this time, Royalty Pharma's Net Debt is fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 14.8 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 132.4 M in 2024.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Royalty Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Royalty Pharma Plc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Royalty Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Royalty Pharma Plc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Royalty Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Royalty Pharma Plc current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	165.6M	161.4M	146.2M	153.5M
Total Assets	17.5B	16.8B	16.4B	17.2B

Other Current Liab Total Assets

Royalty Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Short Long Term Debt Total	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments
Total Assets		0.78	0.59	0.98	-0.33	0.8	0.67	0.54	0.53	0.32	0.39	0.39	0.95	-0.24	0.21	-0.36	-0.17	0.93	0.92	0.88	0.35	0.7	0.86	0.41	0.13	-0.44
Other Current Liab	0.78		0.62	0.76	-0.24	0.42	0.87	0.19	0.23	0.29	0.16	0.25	0.81	-0.27	0.42	-0.3	0.13	0.7	0.6	0.93	0.16	0.15	0.42	0.16	0.03	-0.06
Total Current Liabilities	0.59	0.62		0.53	-0.17	0.26	0.81	0.27	0.18	0.27	0.1	0.83	0.7	-0.25	0.42	-0.25	0.13	0.65	0.56	0.72	-0.01	0.27	0.36	-0.1	-0.19	0.04
Total Stockholder Equity	0.98	0.76	0.53		-0.32	0.83	0.59	0.45	0.48	0.29	0.53	0.29	0.91	-0.25	0.26	-0.35	-0.13	0.91	0.91	0.82	0.23	0.67	0.81	0.4	0.01	-0.51
Other Liab	-0.33	-0.24	-0.17	-0.32		-0.3	-0.2	-0.71	-0.27	-0.29	-0.09	-0.08	-0.33	-0.71	-0.1	0.98	-0.2	-0.33	-0.32	-0.26	-0.08	-0.27	-0.29	-0.25	-0.05	0.25
Accounts Payable	0.8	0.42	0.26	0.83	-0.3		0.18	0.62	0.68	-0.18	0.38	0.17	0.71	-0.23	0.06	-0.25	-0.32	0.74	0.79	0.45	0.07	0.83	0.83	0.78	0.05	-0.87
Cash	0.67	0.87	0.81	0.59	-0.2	0.18		0.23	0.14	0.46	0.0	0.47	0.79	-0.27	0.51	-0.29	0.19	0.7	0.58	0.93	0.32	0.15	0.33	-0.12	0.13	0.2
Other Assets	0.54	0.19	0.27	0.45	-0.71	0.62	0.23		0.63	0.03	-0.16	0.3	0.55	0.28	-0.03	-0.66	-0.19	0.56	0.57	0.34	0.41	0.75	0.69	0.64	0.45	-0.52
Common Stock Shares Outstanding	0.53	0.23	0.18	0.48	-0.27	0.68	0.14	0.63		-0.2	-0.12	0.25	0.46	-0.07	-0.22	-0.18	-0.39	0.59	0.58	0.27	0.12	0.6	0.74	0.72	0.07	-0.57
Short Term Investments	0.32	0.29	0.27	0.29	-0.29	-0.18	0.46	0.03	-0.2		0.32	0.24	0.27	0.35	-0.01	-0.39	0.09	0.27	0.27	0.49	0.54	0.0	0.22	-0.56	0.13	0.52
Inventory	0.39	0.16	0.1	0.53	-0.09	0.38	0.0	-0.16	-0.12	0.32		-0.09	0.29	-0.08	0.3	-0.14	0.11	0.37	0.47	0.19	-0.21	0.28	0.22	-0.17	-0.52	-0.32
Other Current Assets	0.39	0.25	0.83	0.29	-0.08	0.17	0.47	0.3	0.25	0.24	-0.09		0.39	-0.01	-0.12	-0.12	-0.16	0.37	0.32	0.43	0.05	0.26	0.43	-0.07	-0.1	0.12
Total Liab	0.95	0.81	0.7	0.91	-0.33	0.71	0.79	0.55	0.46	0.27	0.29	0.39		-0.34	0.46	-0.37	-0.03	0.96	0.92	0.91	0.34	0.67	0.73	0.34	0.16	-0.39
Treasury Stock	-0.24	-0.27	-0.25	-0.25	-0.71	-0.23	-0.27	0.28	-0.07	0.35	-0.08	-0.01	-0.34		-0.42	-0.68	0.09	-0.32	-0.3	-0.26	0.01	-0.2	-0.08	-0.11	0.0	0.2
Common Stock	0.21	0.42	0.42	0.26	-0.1	0.06	0.51	-0.03	-0.22	-0.01	0.3	-0.12	0.46	-0.42		-0.18	0.53	0.42	0.37	0.37	-0.18	0.07	-0.21	-0.19	-0.22	-0.12
Property Plant Equipment	-0.36	-0.3	-0.25	-0.35	0.98	-0.25	-0.29	-0.66	-0.18	-0.39	-0.14	-0.12	-0.37	-0.68	-0.18		-0.3	-0.36	-0.35	-0.33	-0.11	-0.26	-0.28	-0.14	-0.04	0.17
Intangible Assets	-0.17	0.13	0.13	-0.13	-0.2	-0.32	0.19	-0.19	-0.39	0.09	0.11	-0.16	-0.03	0.09	0.53	-0.3		-0.07	-0.12	0.03	-0.28	-0.34	-0.45	-0.37	-0.27	0.21
Net Tangible Assets	0.93	0.7	0.65	0.91	-0.33	0.74	0.7	0.56	0.59	0.27	0.37	0.37	0.96	-0.32	0.42	-0.36	-0.07		0.98	0.83	0.3	0.74	0.78	0.34	0.05	-0.46
Retained Earnings	0.92	0.6	0.56	0.91	-0.32	0.79	0.58	0.57	0.58	0.27	0.47	0.32	0.92	-0.3	0.37	-0.35	-0.12	0.98		0.75	0.31	0.81	0.82	0.36	0.04	-0.54
Total Current Assets	0.88	0.93	0.72	0.82	-0.26	0.45	0.93	0.34	0.27	0.49	0.19	0.43	0.91	-0.26	0.37	-0.33	0.03	0.83	0.75		0.41	0.37	0.59	0.09	0.19	-0.03
Short Long Term Debt Total	0.35	0.16	-0.01	0.23	-0.08	0.07	0.32	0.41	0.12	0.54	-0.21	0.05	0.34	0.01	-0.18	-0.11	-0.28	0.3	0.31	0.41		0.39	0.46	0.04	0.86	0.19
Net Debt	0.7	0.15	0.27	0.67	-0.27	0.83	0.15	0.75	0.6	0.0	0.28	0.26	0.67	-0.2	0.07	-0.26	-0.34	0.74	0.81	0.37	0.39		0.84	0.6	0.3	-0.73
Non Current Assets Total	0.86	0.42	0.36	0.81	-0.29	0.83	0.33	0.69	0.74	0.22	0.22	0.43	0.73	-0.08	-0.21	-0.28	-0.45	0.78	0.82	0.59	0.46	0.84		0.58	0.28	-0.53
Non Currrent Assets Other	0.41	0.16	-0.1	0.4	-0.25	0.78	-0.12	0.64	0.72	-0.56	-0.17	-0.07	0.34	-0.11	-0.19	-0.14	-0.37	0.34	0.36	0.09	0.04	0.6	0.58		0.29	-0.82
Long Term Debt	0.13	0.03	-0.19	0.01	-0.05	0.05	0.13	0.45	0.07	0.13	-0.52	-0.1	0.16	0.0	-0.22	-0.04	-0.27	0.05	0.04	0.19	0.86	0.3	0.28	0.29		0.05
Cash And Short Term Investments	-0.44	-0.06	0.04	-0.51	0.25	-0.87	0.2	-0.52	-0.57	0.52	-0.32	0.12	-0.39	0.2	-0.12	0.17	0.21	-0.46	-0.54	-0.03	0.19	-0.73	-0.53	-0.82	0.05

Click cells to compare fundamentals

Royalty Pharma Account Relationship Matchups

Royalty Pharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.4B	21.1B	17.5B	16.8B	16.4B	17.2B
Other Current Liab	9.2M	297.1M	165.6M	161.4M	146.2M	153.5M
Total Current Liabilities	333.4M	307.9M	171.3M	1.2B	161.4M	132.4M
Total Stockholder Equity	6.1B	9.9B	5.8B	5.6B	6.5B	6.9B
Accounts Payable	11.2M	10.8M	5.6M	7.9M	15.2M	15.9M
Cash	283.7M	1.0B	1.5B	1.7B	477.0M	343.9M
Other Assets	10.9B	5.1B	13.7B	13.5B	15.5B	16.3B
Common Stock Shares Outstanding	365.9M	375.5M	414.8M	438.0M	602.9M	409.1M
Short Term Investments	509.5M	983M	1.3B	717.0M	18.3M	17.4M
Other Current Assets	92K	8.6M	6.6M	90.5M	3.8M	5.8M
Total Liab	6.3B	6.1B	7.3B	7.3B	6.3B	6.6B
Intangible Assets	51.7M	28.7M	5.7M	14.5M	1.8M	1.7M
Net Tangible Assets	6.1B	4.8B	5.8B	5.6B	6.5B	3.7B
Retained Earnings	2.8B	1.9B	2.3B	2.0B	2.5B	1.4B
Total Current Assets	832.1M	2.7B	2.9B	2.6B	1.3B	1.6B
Short Long Term Debt Total	6.2B	6.1B	14.0B	7.1B	6.1B	8.5B
Net Debt	6.0B	4.8B	5.6B	5.4B	5.7B	5.9B
Non Current Assets Total	11.6B	13.3B	14.6B	14.3B	15.1B	14.2B
Non Currrent Assets Other	88.0M	28.6M	4.1M	15.1M	14.1B	14.8B
Long Term Debt	6.0B	5.8B	7.1B	6.1B	6.1B	6.8B
Cash And Short Term Investments	793.2M	2.0B	2.8B	2.4B	495.3M	470.5M
Net Receivables	38.8M	39.2M	68.3M	727.9M	775.1M	813.8M
Long Term Debt Total	6.0B	5.8B	7.1B	6.1B	7.0B	6.9B
Liabilities And Stockholders Equity	12.4B	21.1B	17.5B	16.8B	16.4B	17.5B
Non Current Liabilities Total	6.0B	5.8B	7.1B	6.1B	6.1B	6.9B
Other Stockholder Equity	(4.3M)	7.9B	3.5B	3.7B	4.0B	3.5B
Net Invested Capital	12.3B	10.6B	12.9B	12.7B	12.7B	13.2B
Long Term Investments	11.5B	13.0B	14.4B	14.1B	15.1B	14.1B
Accumulated Other Comprehensive Income	2.1M	34.4M	16.5M	63K	72.5K	68.8K
Net Working Capital	498.7M	2.4B	2.7B	1.4B	1.1B	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Historical Balance Sheet

Royalty Pharma Inventory

1.09

About Royalty Balance Sheet Analysis

Royalty Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Royalty Pharma balance sheet Correlations

Royalty Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Royalty Pharma balance sheet Accounts

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.98	Total Assets
Property Plant Equipment	+ 0.98	Other Liab
Retained Earnings	+ 0.98	Net Tangible Assets
Net Tangible Assets	+ 0.96	Total Liab
Total Liab	+ 0.95	Total Assets
Net Tangible Assets	+ 0.93	Total Assets

Cash And Short Term Investments	- 0.87	Accounts Payable
Cash And Short Term Investments	- 0.82	Non Currrent Assets Other
Cash And Short Term Investments	- 0.73	Net Debt
Treasury Stock	- 0.71	Other Liab
Other Assets	- 0.71	Other Liab
Property Plant Equipment	- 0.68	Treasury Stock